Search Results

Filter
  • 1-10 of  53,339 results for ""Rituximab""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Low risk of hepatitis B virus reactivation in membranous nephropathy patients with resolved infection undergoing rituximab-based regimens without antiviral prophylaxis.

  • Authors : Song D; Department of Nephropathy, the First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou 450052, Henan, China. Electronic address: .; Guo Y

Subjects: Rituximab*/Rituximab*/Rituximab*/therapeutic use ; Rituximab*/Rituximab*/Rituximab*/adverse effects ; Hepatitis B*/Hepatitis B*/Hepatitis B*/immunology

  • Source: International immunopharmacology [Int Immunopharmacol] 2024 Sep 30; Vol. 139, pp. 112731. Date of Electronic Publication: 2024 Jul 27.Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study.

  • Authors : Shu W; Department of Hematology, Ningbo Medical Center Li Huili Hospital, Ningbo, 315000, China.; Yang Q

Subjects: Rituximab*/Rituximab*/Rituximab*/therapeutic use ; Rituximab*/Rituximab*/Rituximab*/adverse effects ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use

  • Source: Virology journal [Virol J] 2024 Sep 09; Vol. 21 (1), pp. 212. Date of Electronic Publication: 2024 Sep 09.Publisher: BioMed Central Country of Publication: England NLM ID: 101231645 Publication Model: Electronic Cited Medium: Internet ISSN: 1743-422X

Record details

×
Academic Journal

Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection.

  • Authors : Li X; Department of Nephropathy, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.; Song D

Subjects: Rituximab*/Rituximab*/Rituximab*/adverse effects ; Rituximab*/Rituximab*/Rituximab*/therapeutic use ; Glomerulonephritis, Membranous*/Glomerulonephritis, Membranous*/Glomerulonephritis, Membranous*/drug therapy

  • Source: Scientific reports [Sci Rep] 2024 Sep 09; Vol. 14 (1), pp. 20981. Date of Electronic Publication: 2024 Sep 09.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Long-term and low-dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy.

  • Authors : Zheng Y; Department of Neurology, Huashan Hospital Fudan University, Shanghai, China.; National Center for Neurological Disorders (NCND), Shanghai, China.

Subjects: Rituximab*/Rituximab*/Rituximab*/administration & dosage ; Rituximab*/Rituximab*/Rituximab*/adverse effects ; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating*/Polyradiculoneuropathy, Chronic Inflammatory Demyelinating*/Polyradiculoneuropathy, Chronic Inflammatory Demyelinating*/drug therapy

  • Source: Journal of the peripheral nervous system : JPNS [J Peripher Nerv Syst] 2024 Sep; Vol. 29 (3), pp. 350-355. Date of Electronic Publication: 2024 Aug 17.Publisher: Wiley Country of Publication: United States NLM ID: 9704532 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-8027

Record details

×
Academic Journal

Successful Treatment of Epstein-Barr Virus Reactivation-associated Transverse Myelitis Following Herpes Zoster with Intravenous Rituximab in a Cord Blood Transplant Recipient.

  • Authors : Sato K; Department of Hematology, Nagano Red Cross Hospital, Japan.; Watanabe R

Subjects: Rituximab*/Rituximab*/Rituximab*/therapeutic use ; Rituximab*/Rituximab*/Rituximab*/administration & dosage ; Myelitis, Transverse*/Myelitis, Transverse*/Myelitis, Transverse*/drug therapy

  • Source: Internal medicine (Tokyo, Japan) [Intern Med] 2024 Sep 01; Vol. 63 (17), pp. 2445-2450. Date of Electronic Publication: 2024 Feb 01.Publisher: Japanese Society of Internal Medicine Country of Publication: Japan NLM ID: 9204241 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients.

  • Authors : Torgauten HM; Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Subjects: Rituximab*/Rituximab*/Rituximab*/administration & dosage ; Rituximab*/Rituximab*/Rituximab*/therapeutic use ; Rituximab*/Rituximab*/Rituximab*/pharmacology

  • Source: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2024 Sep; Vol. 89, pp. 105770. Date of Electronic Publication: 2024 Jul 15.Publisher: Elsevier B. V Country of Publication: Netherlands NLM ID: 101580247 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.

  • Authors : Marvin-Peek J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Jen WY

Subjects: Leukemia, Hairy Cell*/Leukemia, Hairy Cell*/Leukemia, Hairy Cell*/drug therapy ; Leukemia, Hairy Cell*/Leukemia, Hairy Cell*/Leukemia, Hairy Cell*/mortality ; Leukemia, Hairy Cell*/Leukemia, Hairy Cell*/Leukemia, Hairy Cell*/pathology

  • Source: Leukemia & lymphoma [Leuk Lymphoma] 2024 Sep; Vol. 65 (9), pp. 1325-1334. Date of Electronic Publication: 2024 May 15.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis.

  • Authors : Liu Y; Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.; Jin K

Subjects: Immunoglobulin G4-Related Disease*/Immunoglobulin G4-Related Disease*/Immunoglobulin G4-Related Disease*/diagnosis ; Immunoglobulin G4-Related Disease*/Immunoglobulin G4-Related Disease*/Immunoglobulin G4-Related Disease*/drug therapy ; Immunoglobulin G4-Related Disease*/Immunoglobulin G4-Related Disease*/Immunoglobulin G4-Related Disease*/immunology

  • Source: European journal of internal medicine [Eur J Intern Med] 2024 Sep; Vol. 127, pp. 63-73. Date of Electronic Publication: 2024 Jun 12.Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 9003220 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Evaluation of pediatric rheumatologists' approach to rituximab use: a questionnaire study.

  • Authors : Sunar Yayla EN; Department of Pediatrics, Division of Pediatric Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey. .; Clinic of Pediatric Rheumatology, Ankara Etlik City Hospital, Ankara, Turkey. .

Subjects: Rituximab*/Rituximab*/Rituximab*/therapeutic use ; Rituximab*/Rituximab*/Rituximab*/adverse effects ; Practice Patterns, Physicians'*/Practice Patterns, Physicians'*/Practice Patterns, Physicians'*/statistics & numerical data

  • Source: European journal of pediatrics [Eur J Pediatr] 2024 Sep; Vol. 183 (9), pp. 3959-3968. Date of Electronic Publication: 2024 Jun 26.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7603873 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry.

  • Authors : Riveiro-Barciela M; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.; Liver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Subjects: Rituximab*/Rituximab*/Rituximab*/therapeutic use ; Rituximab*/Rituximab*/Rituximab*/adverse effects ; Hepatitis, Autoimmune*/Hepatitis, Autoimmune*/Hepatitis, Autoimmune*/drug therapy

  • Source: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2024 Sep; Vol. 44 (9), pp. 2303-2314. Date of Electronic Publication: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101160857 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
  • 1-10 of  53,339 results for ""Rituximab""